Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Hamas hands over another body in the Gaza Strip - 2Investigate These Retreats Well known With Seniors
- 3Most loved Amusement Park Firecrackers Show: Which One Lights Up Your Evening?
- 4Kendall Jenner addresses long-standing rumor about her sexuality
- 5Flu illness count nears 5 million, with New York City among the hardest hit
- Burkina Faso forces killed twice as many civilians as jihadists, rights group says
- Virtual Route d: A Survey of \Exploring On the web Stages\ Web Administration
- What is Fusarium graminearum, the fungus a Chinese scientist pleaded guilty to smuggling into the US?
- Experience Is standing by: History's Most noteworthy Travelers
- 21 Incredibly Entertaining Contemplations To Observe Consistently
- Are IDF reservists properly armed during post-war operations?
- ‘Inoculation’ helps people spot political deepfakes, study finds
- Party Urban areas of the World
- 13 must-see moon events in 2026: Eclipses, supermoons, conjunctions and more
